Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;33(3):352-354.
doi: 10.1016/j.annonc.2021.12.001. Epub 2021 Dec 10.

Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study

F Nelli  1 , A Fabbri  2 , A Onorato  2 , D Giannarelli  3 , M A Silvestri  4 , G Pessina  5 , J R Giron Berrios  2 , A Virtuoso  2 , E Marrucci  2 , M Schirripa  2 , M Mazzotta  2 , V Panichi  4 , P Cercola  5 , C Signorelli  2 , M G Chilelli  2 , F Primi  2 , E M Ruggeri  2
Affiliations

Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study

F Nelli et al. Ann Oncol. 2022 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclorure The authors have declared no conflicts of interest.

Figures

Figure 1
Figure 1
Six-month follow-up of antibody responses to full schedule of tozinameran vaccine. (A) Comparison of violin plot distributions and medians of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike protein immunoglobulin G (IgG) titers (logarithmic values). Bars represent median values with 95% confidence interval. (B) Comparison of seroconversion response rates at a cut-off of 50 AU/ml. Timepoint-3: antibody response assessment at 8 weeks after the second tozinameran dose; timepoint-4: antibody response assessment at 6 months after the first tozinameran dose; control cohort: patients with discontinuation of active treatment at least 28 days before assessment of antibody titer at 6 months after the first tozinameran dose; exposed cohort: patients on active treatment within 28 days of antibody titer assessment at 6 months after the first tozinameran dose.
See this image and copyright information in PMC

References

    1. Nelli F., Fabbri A., Onorato A., et al. Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study. Ann Oncol. 2022;33 - PMC - PubMed
    1. Goel R.R., Painter M.M., Apostolidis S.A., et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374 - PMC - PubMed
    1. Eliakim-Raz N., Massarweh A., Stemmer A., Stemmer S.M. Durability of response to SARS-CoV-2 BNT162b2 vaccination in patients on active anticancer treatment. JAMA Oncol. 2021;7:1716–1718. - PMC - PubMed
    1. Waldhorn I., Holland R., Goshen-Lago T., et al. Six-month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors. Cancer Discov. 2021;11:2430–2435. - PubMed
    1. Harvey R.A., Rassen J.A., Kabelac C.A., et al. Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med. 2021;181:672–679. - PMC - PubMed